Latest Financial Results
Q3 2019
Quarter Ended Dec 31, 2018
Stock Information
Company Overview
Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. The company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia, a market that includes 3 to 4 million patients in the U.S. The addressable market may expand significantly if omega-3s demonstrate long-term cardiovascular benefits in on-going third party outcomes studies. Acasti may need to conduct at least one additional clinical trial to support FDA approval of a supplemental New Drug Application to expand CaPre's indications to this segment. Acasti's strategy is to commercialize CaPre in the U.S. and the company is pursuing development and distribution partnerships to market CaPre in major countries around the world.
Investor Contact Information
Company
Acasti Pharma Inc.
545 Promenade du Centropolis
Suite 100, Laval
Québec H7T 0A3
Canada
Investor Relations
Crescendo Communications, LLC
626 RXR Plaza
Uniondale, NY 11566
T: 212-671-1020
ACST@crescendo-ir.com
Transfer Agent
Computershare Trust Company of Canada
650 de Maisonneuve West
7th Floor
Montreal, QC H3A 3T2
T: 514-982-7888
www.computershare.com/ca